拉帕替尼联合卡培他滨治疗HER-2阳性乳腺癌脑转移的疗效:系统评价与汇总分析
该系统评价与汇总分析共纳入12项研究、799例HER-2阳性乳腺癌脑转移患者,评估拉帕替尼单药或联合卡培他滨的疗效。汇总客观缓解率为21.4%(95%CI 11.7-35.9),排除单药拉帕替尼后为29.2%(95%CI 18.5-42.7);中位无进展生存期4.1个月(95%CI 3.1-6.7),中位总生存期11.2个月(95%CI 8.9-14.1)。作者认为,在局部治疗已完成或失败且再程放疗不可行时,可考虑拉帕替尼联合卡培他滨用于脑部进展的HER-2阳性乳腺癌。
要点
- 汇总客观缓解率21.4%,排除单药拉帕替尼后为29.2%。
- 中位无进展生存期4.1个月,中位总生存期11.2个月。
- 作者认为局部治疗已完成或失败且再程放疗不可行时,可考虑拉帕替尼联合卡培他滨。
核心结论
- 由于拉帕替尼对脑转移具有活性,在局部治疗已完成或失败且再程放疗不可行时,可考虑拉帕替尼联合卡培他滨用于脑部进展的HER-2阳性乳腺癌。
研究设计与样本
- 系统评价与汇总分析,检索PubMed、EMBASE、Cochrane图书馆、SCOPUS、Web of Science、ClinicalTrials.gov、世界卫生组织国际临床试验注册平台及欧盟临床试验注册库,纳入12项研究、共799例脑转移患者。
主要发现
- 汇总客观缓解率为21.4%(95%CI 11.7-35.9)。
- 排除接受拉帕替尼单药治疗的患者后,客观缓解率为29.2%(95%CI 18.5-42.7)。
- 汇总中位无进展生存期为4.1个月(95%CI 3.1-6.7),中位总生存期为11.2个月(95%CI 8.9-14.1)。
关键数值与推荐
- 主要终点为客观缓解率和疾病控制率,采用事件数/可评估患者数按固定或随机效应模型进行汇总。
- 次要终点为无进展生存期和总生存期。
临床怎么用
- 作者认为,在局部治疗已完成或失败且再程放疗不可行时,可考虑拉帕替尼联合卡培他滨用于脑部进展的HER-2阳性乳腺癌。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Breast cancer (BC) with HER-2/neu overexpression or amplification (HER-2+) is associated with a higher prevalence of brain metastases (BMs) when compared to other subtypes. Among approved drugs for HER-2+ BC, lapatinib (L) is associated with single agent activity toward BMs. We conducted a systematic review to determine the efficacy of L, singly or in combination with capecitabine (C), as a treatment for HER-2+ BMs. MATERIAL AND METHODS: We searched PubMed, EMBASE, The Cochrane Library, SCOPUS, Web of Science, ClinicalTrials.gov, World Health Organization International Clinical Trials Registry Platform (ICTRP), and the European Union Clinical Trials Register for studies reporting data on L, singly or in combination with C, for the treatment of HER-2+ BC with BMs. Primary end-points were overall response rate (ORR) and disease control rate (DCR); these were pooled to provide an aggregate value. Progression-free survival (PFS) and overall survival (OS) were secondary end-points. Data were pooled using number of events/number of evaluable patients, according to a fixed or random effect model. RESULTS: Overall, 12 studies were included in the present meta-analysis, for a total of 799 patients with BMs. The pooled overall response rate (ORR) was 21.4% (95% CI 11.7-35.9). After exclusion of patients that received L alone, ORR reached 29.2% (95% CI 18.5-42.7). The pooled median PFS and OS were 4.1 (95% CI 3.1-6.7) and 11.2 (95% CI 8.9-14.1) months, respectively. CONCLUSIONS: Due to its activity on BMs, the L + C combination may be considered for HER-2+ BC that has progressed in the brain, when local therapy has been performed or failed and re-irradiation is not feasible.
引用
- Petrelli F, Ghidini M, Lonati V, et al. The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis. Eur J Cancer. 2017. PMID: 28810186. doi:10.1016/j.ejca.2017.07.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。